David Kirn

David Kirn, CEO of 4D Molecular Therapeutics, discusses the development of their gene therapy platform and the tension between platform and product focus. He emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase success. The episode also explores fundraising, regional dynamics of biotech investment, and the benefits of a common technology stack in therapeutic development.